FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

Key Takeaways Vinay Prasad is returning as head of the FDA’s Center for Biologics Evaluation and ResearchHe was reportedly ...

Vinay Prasad has returned to lead the US regulator’s Center for Biologics Evaluation and Research, resuming responsibility ...

Plus more pharma news from the Pharmalittle newsletter.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...

Ukraine and its European allies sought on Sunday to present a united front ahead of a meeting this week between President ...

President Donald Trump announced that he's nominating State Department spokesperson Tammy Bruce to be the next deputy representative of the United States to the United Nations.

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

Dr. Vinay Prasad is back at the FDA less than two weeks after the White House pressed the head of the agency to remove him from his multiple agency leadership roles, an HHS spokesperson said Saturday.

The public deserves to the full story about Dr. Vinay Prasad's temporary resignation and how this might impact regulatory decisions moving forward.

A top Food and Drug Administration official is getting his job back, a spokesman for health agencies said Saturday, less than two weeks after he was ousted at the direction of the White House. Vinay ...